ERISPharmaceuticals
Eris Lifesciences Ltd — Profit & Loss Statement
₹1297.20
+2.05%
Eris Lifesciences Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.72 Cr | 0.51 Cr | 0.38 Cr | 1.17 Cr | — |
| Tax Rate For Calcs | 0.23 | 0.08 | 0.08 | 0.08 | — |
| Normalized EBITDA | 1.03K Cr | 691.91 Cr | 542.82 Cr | 496.83 Cr | — |
| Total Unusual Items | 3.07 Cr | 6.74 Cr | 5.08 Cr | 14.22 Cr | — |
| Total Unusual Items Excluding Goodwill | 3.07 Cr | 6.74 Cr | 5.08 Cr | 14.22 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 351.84 Cr | 392.05 Cr | 382.16 Cr | 406.11 Cr | — |
| Reconciled Depreciation | 315.46 Cr | 182.51 Cr | 117.09 Cr | 64.70 Cr | — |
| Reconciled Cost Of Revenue | 730.10 Cr | 387.64 Cr | 357.08 Cr | 260.81 Cr | — |
| EBITDA | 1.04K Cr | 698.65 Cr | 547.90 Cr | 511.05 Cr | — |
| EBIT | 720.16 Cr | 516.14 Cr | 430.81 Cr | 446.34 Cr | — |
| Net Interest Income | -226.23 Cr | -77.79 Cr | -23.87 Cr | 1.88 Cr | — |
| Interest Expense | 231.29 Cr | 84.80 Cr | 26.17 Cr | 4.15 Cr | — |
| Interest Income | 5.06 Cr | 7.01 Cr | 2.30 Cr | 6.10 Cr | — |
| Normalized Income | 349.49 Cr | 385.82 Cr | 377.46 Cr | 393.06 Cr | — |
| Net Income From Continuing And Discontinued Operation | 351.84 Cr | 392.05 Cr | 382.16 Cr | 406.11 Cr | — |
| Total Expenses | 2.18K Cr | 1.50K Cr | 1.24K Cr | 901.11 Cr | — |
| Rent Expense Supplemental | 2.94 Cr | 3.23 Cr | 2.22 Cr | 3.25 Cr | — |
| Diluted Average Shares | 13.63 Cr | 13.62 Cr | 13.62 Cr | 13.59 Cr | — |
| Basic Average Shares | 13.61 Cr | 13.60 Cr | 13.60 Cr | 13.59 Cr | — |
| Diluted EPS | 25.81 | 28.79 | 28.07 | 29.88 | — |
| Basic EPS | 25.85 | 28.82 | 28.10 | 29.89 | — |
| Diluted NI Availto Com Stockholders | 351.84 Cr | 392.05 Cr | 382.16 Cr | 406.11 Cr | — |
| Net Income Common Stockholders | 351.84 Cr | 392.05 Cr | 382.16 Cr | 406.11 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 351.84 Cr | 392.05 Cr | 382.16 Cr | 406.11 Cr | — |
| Minority Interests | -22.83 Cr | -5.07 Cr | 8.00 Cr | 0.32 Cr | — |
| Net Income Including Noncontrolling Interests | 374.67 Cr | 397.12 Cr | 374.16 Cr | 405.79 Cr | — |
| Net Income Continuous Operations | 374.67 Cr | 397.12 Cr | 374.16 Cr | 405.79 Cr | — |
| Tax Provision | 114.20 Cr | 34.22 Cr | 30.48 Cr | 36.41 Cr | — |
| Pretax Income | 488.87 Cr | 431.34 Cr | 404.64 Cr | 442.20 Cr | — |
| Other Non Operating Income Expenses | 8.58 Cr | 5.12 Cr | 1.24 Cr | 1.04 Cr | — |
| Special Income Charges | -0.91 Cr | -2.64 Cr | -2.06 Cr | -2.39 Cr | — |
| Other Special Charges | 0.90 Cr | 2.14 Cr | 2.00 Cr | 2.39 Cr | — |
| Write Off | 0.01 Cr | 0.50 Cr | 0.05 Cr | 20000.00 | — |
| Net Non Operating Interest Income Expense | -226.23 Cr | -77.79 Cr | -23.87 Cr | 1.88 Cr | — |
| Interest Expense Non Operating | 231.29 Cr | 84.80 Cr | 26.17 Cr | 4.15 Cr | — |
| Interest Income Non Operating | 5.06 Cr | 7.01 Cr | 2.30 Cr | 6.10 Cr | — |
| Operating Income | 703.30 Cr | 495.41 Cr | 422.19 Cr | 425.06 Cr | — |
| Operating Expense | 1.45K Cr | 1.11K Cr | 882.55 Cr | 640.30 Cr | — |
| Other Operating Expenses | 302.51 Cr | 270.06 Cr | 224.74 Cr | 153.89 Cr | — |
| Depreciation And Amortization In Income Statement | 315.46 Cr | 182.51 Cr | 117.09 Cr | 64.70 Cr | — |
| Amortization | 224.38 Cr | 126.97 Cr | 82.66 Cr | — | — |
| Depreciation Income Statement | 91.08 Cr | 55.54 Cr | 34.43 Cr | 64.70 Cr | — |
| Research And Development | 2.44 Cr | 5.72 Cr | 6.10 Cr | 32.74 Cr | — |
| Selling General And Administration | 311.63 Cr | 251.65 Cr | 205.45 Cr | 152.06 Cr | — |
| Selling And Marketing Expense | 254.79 Cr | 180.18 Cr | 158.27 Cr | 101.65 Cr | — |
| General And Administrative Expense | 56.84 Cr | 71.47 Cr | 47.17 Cr | 50.41 Cr | — |
| Rent And Landing Fees | 2.94 Cr | 3.23 Cr | 2.22 Cr | 3.25 Cr | — |
| Gross Profit | 2.15K Cr | 1.60K Cr | 1.30K Cr | 1.07K Cr | — |
| Cost Of Revenue | 730.10 Cr | 387.64 Cr | 357.08 Cr | 260.81 Cr | — |
| Total Revenue | 2.88K Cr | 1.99K Cr | 1.66K Cr | 1.33K Cr | — |
| Operating Revenue | 2.88K Cr | 1.99K Cr | 1.66K Cr | 1.33K Cr | — |
| Total Other Finance Cost | — | — | 0.18 Cr | 0.07 Cr | 0.17 Cr |
| Impairment Of Capital Assets | — | — | — | — | 0.02 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Eris Lifesciences Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.